About Shape Therapeutics
Shape Therapeutics is a Healthcare company based in Seattle (United States) founded in 2018 by Prashant Mali and Francois Vigneault. RNA-targeted therapies are developed to treat multiple diseases. Shape Therapeutics has raised $147.5 million across 2 funding rounds from investors including CureDuchenne Ventures, Decheng Capital and Breton Capital Ventures. The company has 117 employees. Its chief executive, as recorded, is Francois Vigneault. Shape Therapeutics offers products and services including RNAfix, AI-Driven Delivery Platform, and TruStable. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is SHAPE THERAPEUTICS INC. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Shape Therapeutics was founded in 2018 and is based in Seattle, United States, within the biotechnology sector. RNA-targeted therapies are developed to address various diseases through specialized platforms. These include a proprietary suppressor technology enabling premature stop codon readthrough, a precision RNA editing approach utilizing endogenous ADAR enzymes, and an engineered AAV platform for generating tissue-specific vectors. Operations focus on advancing these technologies for therapeutic applications.
- Headquarters Seattle, United States
- Employees 117
- Founders Prashant Mali, Francois Vigneault
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website shapetx.com
- Social LinkedIn X
- Legal Name Shape Therapeutics Inc.
- Total Equity Funding$147.5M (USD)
in 2 rounds
- Latest Funding Round$112M (USD), Series B
Jul 2021
- InvestorsCureDuchenne Ventures
& 5 more
- Employee Count117
Products & Services of Shape Therapeutics
Shape Therapeutics offers a comprehensive portfolio of products and services, including RNAfix, AI-Driven Delivery Platform, and TruStable.
Recruits enzymes to correct RNA mutations for genetic disorder treatment.
Engineers capsids for targeted RNA medicine delivery to specific cells.
Creates stable cell lines for scalable RNA medicine production.
Funding Insights of Shape Therapeutics
Shape Therapeutics has successfully raised a total of $147.5M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $112 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $147.5M
- Total Rounds 2
- Last Round Series B — $112M
- First Round $35.5M
(Nov 2019)
- Investors Count 6
All 2 funding rounds of Shape Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2021 | $112M | Series B | – | Decheng Capital, Breton Capital Ventures | |
| Nov 2019 | $35.5M | Series A | – | New Enterprise Associates |
6 investors in total: 6 institutional.
Investors in Shape Therapeutics
Shape Therapeutics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include CureDuchenne Ventures, Decheng Capital and Breton Capital Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on life science and technology sectors | decheng.com | Shanghai, China | ||
Early-stage tech-focused VC firm investing in geographies such as the US | bretoncapital.com | Boston, United States | ||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Philanthropic assets are managed by Willett Advisors LLC. | willettadvisors.com | New York, United States | ||
Investments in life science startups are made by Mission BioCapital. | missionbiocapital.com | San Francisco, United States | ||
Genetic disorder treatments and care services are supported through ventures. | 2014 | cureduchenne.org/ventures | Newport Beach, United States |
Investor details for Shape Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Shape Therapeutics
16 people are tracked at Shape Therapeutics (10 in leadership, 6 in team); the tracked headcount is 117.
| Name | Role | Group |
|---|---|---|
Prashant Mali | Co-Founder | Leadership |
Francois Vigneault | Co-Founder & CEO | Leadership |
Ron Hause | VP, Head of Analytics and Informatics | Leadership |
Adrian W Briggs | VP, Head of Platform Technologies | Leadership |
Ken Prentice | VP, Head of Process and Product Development | Leadership |
Marsha Mason | Associate Director, Program and Portfolio Management | Leadership |
Brian Booth | Director, Comp Bio RNA Editing | Leadership |
Collin H. | Director, Cell & Vector Engineering | Leadership |
Stephanie Blij | Vice President, Head Of Legal | Leadership |
Kevin Stein | Director Of Computational Biology | Leadership |
Neel Salukhe | Scientist | Team |
David Huss | CSO | Team |
Patrick Bigot | CBO | Team |
Brian Johnson | Senior Scientist II | Team |
Jana Henry (Krieg) | Associate Scientist | Team |
Bridget Fisher | Senior Scientist II | Team |
Complete people profiles for Shape Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Shape Therapeutics
3 dated milestones of Shape Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Shape Therapeutics is founded.
- Funding First funding round of $35.5M.
- Funding Latest funding round, Series B, of $112.0M.
Competitors of Shape Therapeutics
Shape Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of Shape Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Shape Therapeutics
The website of Shape Therapeutics (shapetx.com) receives about 2K visits a month and ranks #11,569,347 among all websites worldwide, #8,133 in Biotechnology and Pharmaceuticals.
- Monthly visits2K
▲ 59.3% vs previous month
- Global rank#11,569,347
among all websites
- Category rank#8,133
Health · Biotechnology and Pharmaceuticals
- Bounce rate35%
- Pages per visit1.9
- Average visit38 sec
- DevicesDesktop 35% · Mobile 65%
Websites whose visitors overlap most with Shape Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| omeros.com | 100% | 15.6K | #1,695,799 | View details | |
| rarecyte.com | 100% | 3.2K | #5,681,690 | View details | |
| dendreon.com | 98% | 17.6K | #885,568 | View details | |
| adaptivebiotech.com | 93% | 63.9K | #807,876 | View details | |
| zymeworks.com | 85% | 32.9K | #989,344 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 20 similar websites and full traffic analytics for Shape Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 20 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Shape Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Shape Therapeutics
Complete news archive for Shape Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Shape Therapeutics
Shape Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Shape Therapeutics is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Francois Vigneault is the CEO of Shape Therapeutics, as recorded in our data. They have also founded this company.
Shape Therapeutics is a funded company, having raised a total of $147.5M across 2 funding rounds to date. The company's 1st funding round was a Series A of $35.5M, raised on Nov 2019.
Shape Therapeutics has 117 employees.
Shape Therapeutics was founded in 2018 and is based in Seattle, United States, within the biotechnology sector. RNA-targeted therapies are developed to address various diseases through specialized platforms. These include a proprietary suppressor technology enabling premature stop codon readthrough, a precision RNA editing approach utilizing endogenous ADAR enzymes, and an engineered AAV platform for generating tissue-specific vectors. Operations focus on advancing these technologies for therapeutic applications.
Shape Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Shape Therapeutics offers RNAfix, AI-Driven Delivery Platform, and TruStable.
Shape Therapeutics has 6 investors. Key investors include CureDuchenne Ventures, Decheng Capital, Breton Capital Ventures, NEA, and Willett Advisors.
Shape Therapeutics operates through Shape Therapeutics Inc..